Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) presented preclinical and translational data on its clinical asset, CT-95, at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The …
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 clinical trial of CT-95, a bispecific antibody designed to target …
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers Read More PHILADELPHIA, PA — Context Therapeutics Inc. has confirmed its presence at several prominent investor conferences scheduled over the coming months. The company will update investors on its innovative pipeline, including …
Context Therapeutics Announces Participation in Key Investor Conferences Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced that new research on its clinical asset, CT-95, will be unveiled at the American Association for Cancer Research (AACR) Annual Meeting …
Context Therapeutics to Showcase CT-95 Data at AACR 2025 Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has reported its financial results for the year ending December 31, 2024, while highlighting advancements in its clinical pipeline.
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the issuance of non-qualified stock option awards to two newly hired employees as part of an inducement to join the company. …
Context Therapeutics Grants Stock Options to New Employees Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced its participation in several upcoming investor conferences.
Context Therapeutics to Showcase at Top 2025 Investor Conferences Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental treatment is a …
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Andy Pasternak as Chairman of its Board of Directors, following the departure of Richard Berman, who stepped down …
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, has reported its financial results for the third quarter ending September 30, 2024, alongside significant corporate milestones. The …
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances Read More